A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Stopped early · Phase 2
Conditions studied: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Carcinoma, Endometrioid Adenocarcinoma
In brief
This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometroid ovarian cancer. Patients entering the following cohorts must have BRCA mutational status confirmed by a central lab: * Cohort A1: No BRCA mutation in tumor; high level of LOH (loss of heterozygosity) * Cohort A2: BRCA mutation in tumor
Key facts
- Study ID
- NCT03824704
- Run by
- pharmaand GmbH
- People needed
- 1
- Starts
- 2019-08-23
- Expected to finish
- 2020-08-24
- Last updated by the study team
- 2023-06-12
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Community Cancer Institute — Clovis, California, United States
- Memorial Health University Medical Center — Savannah, Georgia, United States
- Women's Cancer Care — Covington, Louisiana, United States
- Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
- University of Vermont Medical Center — Burlington, Vermont, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.